Chiu Sung K, Furlong Eliska, McKinnon Elizabeth J, Fox Annette, Ovando Stephany Sánchez, Carolan Louise, McLean-Tooke Andrew, Oommen Joyce, Yeoh Daniel K, Cheung Laurence C, Gottardo Nicholas G, Kotecha Rishi S
Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Curtin Medical School, Curtin University, Perth, WA, Australia.
NPJ Vaccines. 2025 Aug 26;10(1):203. doi: 10.1038/s41541-025-01256-0.
Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule. This comprised three vaccine doses for children <9 years of age and two doses for those ≥9 years, with each dose administered at least 4 weeks apart. The additional vaccine dose was well-tolerated with no serious adverse events reported; it also resulted in improved geometric mean antibody titres for A/H1N1 (70 to 97, p = 0.003), A/H3N2 (76 to 104, p = 0.003) and B/Washington (148 to 179, p = 0.03) strains. In summary, a boosted influenza vaccine schedule is safe and improves humoral immune response, providing a readily implementable strategy to protect children undergoing treatment for cancer.
当前的免疫接种指南建议，9岁及以上儿童接种一剂流感疫苗，年龄较小或未接种过疫苗的儿童接种两剂。然而，接受化疗的儿童免疫反应减弱。我们在西澳大利亚珀斯儿童医院对接受癌症治疗的儿童进行了一项前瞻性开放标签研究，以检验强化流感疫苗接种方案的安全性和有效性。该方案包括对9岁以下儿童接种三剂疫苗，对9岁及以上儿童接种两剂，每剂间隔至少4周。额外的疫苗剂量耐受性良好，未报告严重不良事件；它还使A/H1N1（从70升至97，p = 0.003）、A/H3N2（从76升至104，p = 0.003）和B/华盛顿（从148升至179，p = 0.03）毒株的几何平均抗体滴度有所提高。总之，强化流感疫苗接种方案是安全的，可改善体液免疫反应，为保护接受癌症治疗的儿童提供了一种易于实施的策略。
